10-12 September 2018 //  Lancaster Royal Hotel, London


Joseph Rabinowitz

Dr Joseph Rabinowitz

Senior Director of AAV Capsid Development, Pfizer

Joseph Rabinowitz recently joined Pfizer as the Senior Director of AAV Capsid Development. He received his PhD from Case Western Reserve University studying the effects of generating a secreted mutation of Neural Cell Adhesion Molecule (NCAM) by homologous recombination in embryonic stem cells on embryonic development generating one of the first heterozygous embryonic lethal mutations. He then moved to the University of North Carolina at Chapel Hill as a postdoctoral researcher in the laboratory of R. Jude Samulski. Studying the capsid of AAV2, generating mutation by random insertion of peptides in the capsid, then standardization of AAV1-5 helper plasmids and demonstrating that different serotype capsid subunit interfaces can generate intact virions with unique properties. As a faculty member first at Thomas Jefferson University and then at Temple University School of Medicine, both in Philadelphia Pennsylvania, he established vector cores for the production of AAV, adenovirus and lentivirus. In addition, contributions were made to understanding the tropisms of AAV serotypes 1-9 after systemic and direct left ventricular luminal injection. 



2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad